Inflammatory cytokines following diethylcarbamazine (DEC) treatment of different clinical groups in lymphatic filariasis.
In an earlier study in Indonesia we reported on adverse reactions to diethylcarbamazine (DEC) in brugian filariasis patients identified as microfilaraemics (n = 26), endemic normals (n = 11) and elephantiasis patients (n = 17). To assess the link between adverse reactions and cytokines we have now analysed an array of inflammatory mediators in plasma samples collected during the same study. Pre-treatment levels of interleukin (IL)-6 and soluble tumour necrosis factor receptor 75 (sTNF-R75) were higher in elephantiasis patients compared to microfilaraemics and endemic normals, indicating the presence of an ongoing inflammation in patients with chronic disease. After initiation of treatment, the levels of IL-6 and LPS-binding protein (LBP) were consistently and significantly higher in microfilaraemics who suffered most from adverse reactions compared with endemic normals and elephantiasis patients. In microfilaraemics the levels of sTNF-R75 increased after treatment to reach levels recorded in elephantiasis patients. IL-6 increased early, concurrent with the development of adverse reactions and peaked by 24 h post treatment. The levels of LBP and sTNF-R75 in microfilaraemics also increased to peak, later than IL-6, at 32 h post DEC therapy. Although changes were recorded in IL-8 and IL-10 levels in some individuals, no significant differences were found between the 3 clinical groups. These results demonstrate that intake of DEC leads to an increase in a selected number of inflammatory mediators in the group of filarial patients who suffer most from adverse systemic reactions.
Haarbrink
M
M
Department of Parasitology, Leiden University Medical Centre, The Netherlands.
Terhell
A J
AJ
Abadi
G K
GK
Mitsui
Y
Y
Yazdanbakhsh
M
M
D000209:Acute-Phase Proteins; D000293:Adolescent; D000328:Adult; D000368:Aged; D002352:Carrier Proteins / Q000378:metabolism; D002648:Child; D016207:Cytokines / Q000378:metabolism*; D004049:Diethylcarbamazine / Q000097:blood / Q000627:therapeutic use*; D004605:Elephantiasis, Filarial / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D005369:Filaricides / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D007378:Interleukins / Q000378:metabolism; D008297:Male; D008562:Membrane Glycoproteins; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D000099231:Lipopolysaccharide-Binding Protein
D000209:Acute-Phase Proteins; D002352:Carrier Proteins; D016207:Cytokines; D004049:Diethylcarbamazine; D005369:Filaricides; D007378:Interleukins; D008562:Membrane Glycoproteins; D014409:Tumor Necrosis Factor-alpha; D000099231:Lipopolysaccharide-Binding Protein